Evidence map›Paper›PMID 38896194›Full record

ArticlePurinergic signalling2024

Correction to: Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist.

Jessica Nagel, Olli Törmäkangas, Katja Kuokkanen, Ali El-Tayeb, Josef Messinger, Aliaa Abdelrahman, Christiane Bous, Anke C Schiedel, Christa E Müller

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jessica NagelPharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Pharmaceutical & Medicinal Chemistry, An der Immenburg 4, 53121, Bonn, Germany.
Olli TörmäkangasOrion Pharma, Orion Corporation, Tengströminkatu 8, FI-20360 Turku, and Orionintie 1A, 02200, Espoo, FI, Finland.
Katja KuokkanenOrion Pharma, Orion Corporation, Tengströminkatu 8, FI-20360 Turku, and Orionintie 1A, 02200, Espoo, FI, Finland.
Ali El-TayebPharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Pharmaceutical & Medicinal Chemistry, An der Immenburg 4, 53121, Bonn, Germany.
Josef MessingerOrion Pharma, Orion Corporation, Tengströminkatu 8, FI-20360 Turku, and Orionintie 1A, 02200, Espoo, FI, Finland.
Aliaa AbdelrahmanPharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Pharmaceutical & Medicinal Chemistry, An der Immenburg 4, 53121, Bonn, Germany.
Christiane BousPharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Pharmaceutical & Medicinal Chemistry, An der Immenburg 4, 53121, Bonn, Germany.
Anke C SchiedelPharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Pharmaceutical & Medicinal Chemistry, An der Immenburg 4, 53121, Bonn, Germany.
Christa E MüllerPharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Pharmaceutical & Medicinal Chemistry, An der Immenburg 4, 53121, Bonn, Germany. christa.mueller@uni-bonn.de.ORCID http://orcid.org/0000-0002-0013-6624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38896194
PMCPMC11555128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.